import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "ipamorelin-complete-guide",
  title: "Ipamorelin: The Complete Research Guide (2026)",
  description:
    "Ipamorelin is one of the most selective GH secretagogues in preclinical research. This complete guide covers its mechanism of action, receptor pharmacology, research protocols, combination strategies, and how it compares to other GHRP compounds.",
  category: "Compound Profiles",
  readMinutes: 12,
  publishedAt: "2026-06-05",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) is a synthetic pentapeptide growth hormone secretagogue and selective agonist of the GHSR-1a (growth hormone secretagogue receptor 1a). First described in the late 1990s by Novo Nordisk researchers, it has become one of the most frequently studied GH-releasing peptides due to a combination of potency, selectivity, and a favorable side-effect profile relative to older GHRPs.",
    },
    {
      type: "heading",
      text: "What Is Ipamorelin?",
    },
    {
      type: "paragraph",
      text: "Ipamorelin belongs to the GHRP (growth hormone releasing peptide) family — a class of compounds that stimulate GH release via GHSR-1a rather than acting directly on pituitary somatotrophs as GH analogs do. The key distinction between ipamorelin and earlier GHRPs (GHRP-2, GHRP-6) is its receptor selectivity: ipamorelin activates GHSR-1a without significantly stimulating ACTH, cortisol, or prolactin release at research-relevant doses.",
    },
    {
      type: "list",
      items: [
        "Molecular formula: C₃₈H₄₉N₉O₅",
        "Molecular weight: 711.87 Da",
        "Receptor target: GHSR-1a (ghrelin receptor)",
        "Peptide class: Growth hormone secretagogue / GHRP",
        "Research route: Typically subcutaneous or intraperitoneal in animal models",
        "Half-life: Approximately 2 hours in preclinical models",
      ],
    },
    {
      type: "heading",
      text: "Mechanism of Action",
    },
    {
      type: "paragraph",
      text: "Ipamorelin acts as a ghrelin mimetic, binding GHSR-1a expressed on somatotroph cells in the anterior pituitary. This initiates intracellular signaling — primarily through Gαq/11 coupling and phospholipase C activation — that elevates intracellular calcium and triggers pulsatile GH release.",
    },
    {
      type: "subheading",
      text: "GHSR-1a Agonism",
    },
    {
      type: "paragraph",
      text: "The ghrelin receptor (GHSR-1a) is constitutively active at approximately 50% of its maximum in the absence of ligand. Ipamorelin acts as a full agonist at this receptor, amplifying somatotroph GH pulse amplitude while preserving natural pulsatility — a critical advantage over exogenous GH administration, which suppresses endogenous secretion.",
    },
    {
      type: "subheading",
      text: "Selectivity Profile",
    },
    {
      type: "paragraph",
      text: "What distinguishes ipamorelin pharmacologically is its narrow receptor selectivity. In multiple preclinical studies, ipamorelin at doses that produce significant GH release failed to significantly elevate ACTH, cortisol, or prolactin — unlike GHRP-2, which stimulates cortisol and prolactin at supra-physiological doses, or GHRP-6, which strongly activates appetite pathways via ghrelin receptor cross-talk with NPY circuits.",
    },
    {
      type: "list",
      items: [
        "Ipamorelin: Highly selective — minimal ACTH/cortisol/prolactin stimulation",
        "GHRP-2: GH release + cortisol + prolactin elevation (less selective)",
        "GHRP-6: GH release + significant appetite stimulation (ghrelin pathway overlap)",
        "Hexarelin: Potent GH release + cardiac CD36 binding, cortisol elevation at higher doses",
      ],
    },
    {
      type: "heading",
      text: "Key Research Findings",
    },
    {
      type: "subheading",
      text: "Bone Mineral Density",
    },
    {
      type: "paragraph",
      text: "One of the most cited early studies (Svensson et al., 1998, Journal of Endocrinology) demonstrated that ipamorelin increased bone mineral content in young female rats following 12 weeks of administration, with the effect appearing independent of cortisol elevation — supporting its cleaner selectivity profile compared to GHRP-2.",
    },
    {
      type: "subheading",
      text: "Body Composition",
    },
    {
      type: "paragraph",
      text: "Preclinical models have consistently shown ipamorelin-associated improvements in lean mass and reductions in adiposity, attributed to GH-mediated IGF-1 elevation and downstream lipolytic and anabolic signaling. The preserved pulsatility of GH release (versus continuous GH analog dosing) appears to maintain receptor sensitivity over longer study durations.",
    },
    {
      type: "subheading",
      text: "GI Motility",
    },
    {
      type: "paragraph",
      text: "A separate research thread has examined ipamorelin's effects on gastrointestinal motility. Studies in postoperative ileus models showed that ipamorelin accelerated GI recovery, likely through GHSR-1a expression in enteric neurons. This line of research was carried forward into clinical investigation by Helsinn Healthcare (Phase II/III for postoperative ileus), providing some of the limited human pharmacokinetic data available.",
    },
    {
      type: "subheading",
      text: "Aging and Somatopause",
    },
    {
      type: "paragraph",
      text: "Given the decline in GH secretion with age (somatopause), ipamorelin has been studied as a tool to restore more youthful GH pulsatility in aged animal models. Researchers have noted recovery of IGF-1 levels, improvements in lean-to-fat ratio, and markers associated with improved metabolic function — without the desensitization observed with continuous GH analog exposure.",
    },
    {
      type: "heading",
      text: "Research Protocols",
    },
    {
      type: "subheading",
      text: "Typical Dosing Ranges in Animal Models",
    },
    {
      type: "paragraph",
      text: "In rodent research, ipamorelin has been studied at doses ranging from 100 mcg/kg to 1 mg/kg, administered subcutaneously or intraperitoneally. The most commonly cited doses in the literature fall in the 200–300 mcg/kg range for GH-axis studies.",
    },
    {
      type: "callout",
      text: "Research Note: All dosing information refers to animal research protocols. Ipamorelin is not approved for human use and these figures do not constitute medical guidance.",
    },
    {
      type: "subheading",
      text: "Timing Considerations",
    },
    {
      type: "paragraph",
      text: "GH is secreted in pulses, with the largest pulse typically occurring during slow-wave sleep. Research protocols often time ipamorelin administration to mimic or augment these natural peaks — typically in the evening or at sleep onset in rodent circadian models. Studies examining multiple daily administrations have generally used 2–3 injections spaced across the active period.",
    },
    {
      type: "subheading",
      text: "Combination Protocols",
    },
    {
      type: "paragraph",
      text: "Ipamorelin is frequently studied in combination with GHRH analogs, most commonly CJC-1295 (without DAC) or modified GRF(1-29). The mechanistic rationale is synergy: GHRH analogs act on a distinct receptor (GHRHR) and work through cAMP/PKA signaling, while ipamorelin works through GHSR-1a and calcium signaling. When co-administered, the two pathways amplify GH pulse amplitude greater than either compound alone.",
    },
    {
      type: "list",
      items: [
        "Ipamorelin alone: Moderate GH pulse amplification via GHSR-1a",
        "CJC-1295 (no DAC) alone: Moderate amplification via GHRHR/cAMP",
        "Ipamorelin + CJC-1295: Synergistic amplification — greater than additive in most models",
        "Timing: Co-administration timed to same injection is standard in combination research",
      ],
    },
    {
      type: "heading",
      text: "Ipamorelin vs. Other GHRPs",
    },
    {
      type: "table",
      headers: ["Compound", "Selectivity", "Appetite Effect", "Cortisol Effect", "GH Potency"],
      rows: [
        ["Ipamorelin", "High", "Minimal", "Minimal", "Moderate-High"],
        ["GHRP-2", "Moderate", "Mild", "Moderate", "High"],
        ["GHRP-6", "Moderate", "Significant", "Mild", "High"],
        ["Hexarelin", "Low-Moderate", "Mild", "Moderate", "Very High"],
        ["Sermorelin", "N/A (GHRH class)", "None", "None", "Moderate"],
      ],
    },
    {
      type: "paragraph",
      text: "The selectivity advantage of ipamorelin makes it the preferred GHRP in longevity and body composition research where investigators specifically want to isolate GH axis effects without confounding cortisol elevation or appetite stimulation.",
    },
    {
      type: "heading",
      text: "Ipamorelin and Tachyphylaxis",
    },
    {
      type: "paragraph",
      text: "A recurring concern with GH secretagogues is receptor desensitization (tachyphylaxis) with chronic use. Ipamorelin studies suggest lower desensitization risk compared to GHRP-2 and GHRP-6 — attributed to its partial agonist-like kinetics at high concentrations and the preservation of pulsatile delivery patterns. Cycling protocols (e.g., 5 days on / 2 days off, or 12 weeks on / 4 weeks off) are commonly used in longer-term research designs to mitigate any receptor downregulation.",
    },
    {
      type: "heading",
      text: "Sourcing Considerations for Researchers",
    },
    {
      type: "paragraph",
      text: "Ipamorelin purity and the accuracy of peptide sequence verification are critical in research settings. Contamination or sequence errors introduce confounding variables that invalidate experimental conclusions. Key quality indicators when evaluating ipamorelin for research include:",
    },
    {
      type: "list",
      items: [
        "HPLC purity certificate: ≥98% purity is the research standard",
        "Mass spectrometry (MS) verification: Confirms correct molecular weight and sequence",
        "Endotoxin (LAL) testing: Critical for in vivo research to avoid pyrogenic responses",
        "Third-party CoA: Independent lab verification — not internal documentation only",
        "Lyophilized form: Indicates proper manufacturing and stability for long-term storage",
      ],
    },
    {
      type: "heading",
      text: "Summary",
    },
    {
      type: "paragraph",
      text: "Ipamorelin occupies a distinct niche in peptide research: a selective, well-characterized GHSR-1a agonist with a two-decade literature base and an unusually clean receptor profile. Its combination with GHRH analogs represents one of the most studied GH axis research paradigms available, and its low desensitization profile makes it suitable for longer-term study designs. For researchers focused on GH axis, aging, body composition, or GI motility, ipamorelin remains a primary reference compound.",
    },
    {
      type: "disclaimer",
      text: "This article is intended for researchers and is provided for educational and scientific informational purposes only. Ipamorelin is not approved by the FDA for human therapeutic use. Nothing in this article constitutes medical advice, and no information herein should be construed as a recommendation to use any compound in humans.",
    },
  ],
};
